Insight and Perspective on Omicron’s Development, Behaviour, and Vaccine Breakthrough: Next Sequelae of COVID-19

Background: The Severe Acute Respiratory Coronavirus (SARS-CoV-2) has emerged in a variety of forms since its first appearance in early December 2019. The Omicron variation (B.1.1.529) was recently confirmed as a relatively new Variant of Concern (VOC). There are several mutations in this S-protein, making it an exclusively lethal version of the protein. Omicron variants feature multiple mutations clustered in a region of S protein that is the principal target of antibodies, and these mutations may have an impact on the binding affinities of antibodies to the S protein, as demonstrated by structural analysis. Materials and Methods: Google, Sciencedirect, Web of science, and ResearchGate databases have been explored for potentially existing research to obtain the most emerging trends and up-todate metadata on various perspectives of Omicron variants. Conclusion: There is evidence that the Omicron variant’s mutations may interfere with antibody binding in people who have been exposed to the SARS-CoV-2 virus in the past. At the moment, there is very little information on the Omicron version. Therefore, mutation dispersion evaluations, evolutionary links to previous variants, and putative structural effects on antibody binding effects are all explored in this work. Results: In the current state of pandemic crises, the comprehension of Omicron will pave a path for healthcare professionals to treat infectious conditions very well.